Clinical trials: sponsored by Sinocelltech Ltd.
COVID-19
Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023
About 15,000 to 25,000 subjects will be screened. Their information will be collected, venous blood will be sampled, their serum antibody levels will be detected, and the incidence of COVID-19 wil be followed up.
- Trial name
- COVID-19 (NCT05758675)
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Wet Age-related Macular Degeneration
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.
- Trial name
- NCT05480293
- Testing
- Ranibizumab, SCT510A
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Sinocelltech Ltd.
COVID-19 SARS-CoV-2 Infection
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
The objective of this study is to evaluate the effectiveness of SCTV01E in healthy people
- Trial name
- NCT05683561
- Testing
- CoronaVac, SCTV01E
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Head and Neck Squamous Carcinoma
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The study is to explore the efficacy and safety of SCT200 with SCT-I10A or SCT200 combined with paclitaxel/docetaxel in the treatment of recurrent/metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT05552807
- Testing
- SCT-I10A, SCT200, paclitaxel
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with mRNA-1273 (the mRNA COVID-19 vaccine from Moderna) in population aged…
- Trial name
- NCT05345873
- Testing
- SCTV01E, mRNA-1273
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with Comirnaty.
- Trial name
- NCT05329051
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster.
- Trial name
- NCT05239806
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, Sars-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.
- Trial name
- NCT05238441
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥18 years and previously fully immunized with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with…
- Trial name
- NCT05238454
- Testing
- SCTV01C, Sinopharm inactivated COVID-19 vaccine, Comirnaty
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 \& SCTA01C compared to placebo in addition to Standard of…
- Trial name
- NCT05156645
- Testing
- SCTA01 and SCTA01C
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.
- Trial name
- NCT05043285
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
- Trial name
- NCT05043311
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Interventional, Prevention
A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years
A phase II random, double blind, positive and placebo control trail was conducted in 1200 healthy women in the arm A: 18-26 years old and 600 healthy women in the Arm B: 27-45 years old.
- Conditions
- Interventional, Prevention, Randomized
- Trial name
- NCT05060484
- Testing
- SCT1000, Gardasil®9, Gardasil®
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
HPV Infection Vaccine Safety SCT1000
A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years
A phase 1 random, double blind, positive and placebo control trail was conducted in 120 healthy women in the arm A: 18-26 years old and Arm B: 27-45 years old.
- Trial name
- NCT04921111
- Testing
- SCT1000, Gardasil®9, Gardasil®
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV-2
To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.
- Trial name
- MAOP3 (NCT04709328)
- Testing
- SCTA01
- Volunteers
- 690 people
- Sponsor
- Sinocelltech Ltd.
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Healthy
Pharmacokinetics and Safety in Healthy Volunteers
Investigate the pharmacokinetics, safety and tolerability of SCT630 and to establish pharmacokinetic similarity of SCT630 to adalimumab.
- Trial name
- NCT03917628
- Testing
- SCT630, adalimumab-EU source
- Where
- China
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care
This is an adaptive, randomized, double-blinded, placebo-controlled, Phase II/III study conducted to evaluate the effect of SCTA01 on participant survival and clinical efficacy in participants with severe COVID-19 admitted to…
- Trial name
- NCT04683328
- Testing
- SCTA01
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.